Schizophrenia

• A randomised, controlled trial to investigate the effect of a four/six week intensified pharmacological treatment for schizophrenia, major d … Not authorised
  2022-502185-24-00 5 "Schizophrenia, schizoaffective disorder, schizophreniform di"
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age) Pending
  2025-523711-11-00 5
• A Phase 2 Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults with Schizophrenia (STAR-1) Pending
  2025-524058-32-00 4
• Phase 3 Evaluation of KarXT and KarXT+KarX-EC in Schizophrenia and Autism-Related Irritability in Youth, respectively. Pending
  2025-524062-16-00 5 "Schizophrenia and Autism Spectrum Disorder (ASD)"
• Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics Recruiting
  2024-519836-18-00 5 2025-12-16 "treatment-resistant schizophrenia (TRS)"
• Long-Term Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia Recruiting
  2025-521216-19-00 5 2025-12-10
• A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for schizophrenia compared to t … Recruiting
  2023-506602-39-00 6 2024-08-01 "schizophrenia, schizoaffective disorder, schizophrenifom dis"
• Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia Recruiting
  2024-513222-30-00 5 2020-02-20 "Adolescent patient (13-17 years of age) with Schizophrenia"
• Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia Recruiting
  2025-521868-35-00 4 2026-04-08
• Assessment of microglial activation in patients with schizophrenia stratified for C4 complement by PET using [18F]DPA-714 Recruiting
  2023-504181-38-00 10 2025-11-17 "pathology studied is schizophrenia"
• Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat) Recruiting
  2024-514457-30-00 4 2024-02-26
• A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLU … Recruiting
  2023-507372-42-00 4 2021-09-20
• The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatm … Ended
  2025-523325-18-00 2 2025-10-15 "Bioequivalence study under fasting conditions"
• A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Adaptive Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Phar … Ended
  2025-521914-25-00 3 2025-07-31
• The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatm … Ended
  2025-521400-21-00 2 2025-05-15 "Not applicable (submitted trial is a BE study in healthy sub"
• An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants with Schizophrenia Ended
  2023-505664-11-00 3 2024-06-19
• An adaptive, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of RL-007 in the treatment of cognitive … Ended
  2023-506570-12-01 4 2024-06-13 "Cognitive disorder"
• Safety and efficacy of olanzapine treatment in psychosis: Effect of genetic and epigenetic factors – covariates of treatment response Ended
  2022-502902-33-00 6 2023-10-24 "Psychoses"
• A rollover study for subjects that complete KAR-012 trial, to assess Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with … Ended
  2024-510773-20-00 5 2023-06-12
• A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) Ended
  2024-510770-25-00 5 2023-03-22
• A Randomized, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Relative Bioavailability of LY03010 versus Xeplion® after Intram … Ended
  2022-502179-48-00 2 2023-02-23
• Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia Ended
  2023-508433-14-00 5 2022-09-30
• Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 years of age) with Schizophrenia Ended
  2024-513194-44-00 5 2021-12-14 "Adolescent Patients (13 to 17 years of age) with Schizophren"
• Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Ended
  2022-502233-25-00 5

Showing 1–24 of 24 trials